L-天冬氨酸,N-[1-[[(1,1-二甲基乙基)氨基]羰基]-2-甲基丙基]-,4-[1-[[(1,1-二甲基乙基)氨基]羰基]-2-甲基丙基]1-甲基酯,[S-(R*,R*)]-(9CI) | 142344-87-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: L-天冬氨酸,N-[1-[[(1,1-二甲基乙基)氨基]羰基]-2-甲基丙基]-,4-[1-[[(1,1-二甲基乙基)氨基]羰基]-2-甲基丙基]1-甲基酯,[S-(R*,R*)]-(9CI)
• 中文别名: 5-氨基-1-[(2R,3R,4S,5R)-3,4-二羟基-5-[(苯基甲基氨基)甲基]四氢呋喃-2-基]咪唑-4-甲酰胺
• 英文名称: 5-amino-1-β-D-(5-benzylamino-5-deoxy-1-β-D-ribofuranosyl)imidazole-4 carboxamide
• 英文别名: GP-531；5-amino-1-β-D-(5-benzylamino-5-deoxyribofuranosyl)imidazole-4-carboxamide；5-amino-1-[(2R,3R,4S,5R)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide
• CAS: 142344-87-4
• 化学式: C₁₆H₂₁N₅O₄
• 分子量: 347.374
• InChiKey: LECUGLHMNZTZQB-XNIJJKJLSA-N

物化性质

• 沸点：
  703.1±60.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：125 mg/mL（359.85 mM）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  149
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT
  申请人：Stover Richard R.

  公开号：US20080175891A1

  公开（公告）日：2008-07-24

  The present invention provides transdermal administration of AICA riboside, or a prodrugs, analogs, or salts thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

  本发明提供了通过经皮途径给予AICA核糖苷，或其前药、类似物或盐，和/或血液凝块抑制剂以预防或减少患者的不良副作用。可能受益的患者类型包括左心室功能减退的患者、先前发生心肌梗死的患者、接受非血管手术的患者，或分娩期间的胎儿。
• Methods, Compositions, and Formulations for Preventing or Reducing Adverse Effects in a Patient
  申请人：Mangano T. Dennis

  公开号：US20060293273A1

  公开（公告）日：2006-12-28

  The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

  本发明提供了与阿卡德西酮、其前药、类似物或盐有关的方法、组合物、配方和试剂盒，以及/或用于预防或减少患者不良副作用的血凝抑制剂。可能受益的患者类型包括左心室功能下降的患者、先前发生心肌梗死的患者、接受非血管手术的患者或分娩期间的胎儿。
• Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
  申请人：Pericor Therapeutics, Inc.

  公开号：EP2594273A1

  公开（公告）日：2013-05-22

  The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

  本发明提供了与阿卡替辛或其原药、类似物或盐和/或凝血抑制剂有关的方法、组合物、制剂和试剂盒，用于预防或减少患者的不良副作用。可能受益的患者类型包括左心室功能减退的患者、既往患有心肌梗塞的患者、接受非血管手术的患者或分娩期间的胎儿。
• AICA RIBOSIDE ANALOGS FOR TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE
  申请人：Pericor Therapeutics, Inc.

  公开号：EP3269374A1

  公开（公告）日：2018-01-17

  The present disclosure provides methods and compositions for treating acute heart failure, by administering to a subject in need thereof a therapeutically effective amount of an AICA riboside analog or a pharmaceutically acceptable salt or prodrug thereof.

  本公开提供了治疗急性心力衰竭的方法和组合物，其方法是向有需要的受试者施用治疗有效量的 AICA 核苷类似物或其药学上可接受的盐或原药。
• AICA RIBOSIDE ANALOGS
  申请人：Metabasis Therapeutics Inc.

  公开号：EP0495091B1

  公开（公告）日：1999-11-24